REGENXBIO Inc. (NASDAQ:RGNX) insider Kenneth T. Mills sold 10,500 shares of the company’s stock in a transaction that occurred on Tuesday, September 5th. The stock was sold at an average price of $25.00, for a total value of $262,500.00. Following the sale, the insider now owns 118,530 shares of the company’s stock, valued at approximately $2,963,250. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

REGENXBIO Inc. (NASDAQ:RGNX) traded up 1.43% on Thursday, reaching $24.80. The company’s stock had a trading volume of 249,197 shares. REGENXBIO Inc. has a 52-week low of $12.81 and a 52-week high of $25.00. The firm has a 50-day moving average price of $20.30 and a 200 day moving average price of $19.76. The firm’s market capitalization is $766.17 million.

REGENXBIO (NASDAQ:RGNX) last announced its quarterly earnings results on Tuesday, August 8th. The biotechnology company reported ($0.47) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.81) by $0.34. REGENXBIO had a negative return on equity of 38.74% and a negative net margin of 839.87%. The company had revenue of $6.56 million during the quarter. Equities analysts anticipate that REGENXBIO Inc. will post ($2.87) earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: “REGENXBIO Inc. (RGNX) Insider Kenneth T. Mills Sells 10,500 Shares” was reported by American Banking News and is the sole property of of American Banking News. If you are accessing this piece on another website, it was stolen and reposted in violation of U.S. and international copyright and trademark legislation. The original version of this piece can be viewed at https://www.americanbankingnews.com/2017/09/07/regenxbio-inc-rgnx-insider-kenneth-t-mills-sells-10500-shares.html.

Hedge funds have recently made changes to their positions in the business. Redmile Group LLC acquired a new position in REGENXBIO during the 1st quarter worth $24,494,000. Victory Capital Management Inc. boosted its position in REGENXBIO by 30.9% during the 1st quarter. Victory Capital Management Inc. now owns 46,969 shares of the biotechnology company’s stock worth $907,000 after acquiring an additional 11,079 shares during the period. Acadian Asset Management LLC acquired a new position in REGENXBIO during the 1st quarter worth $272,000. Schwab Charles Investment Management Inc. boosted its position in REGENXBIO by 6.2% during the 1st quarter. Schwab Charles Investment Management Inc. now owns 73,724 shares of the biotechnology company’s stock worth $1,423,000 after acquiring an additional 4,275 shares during the period. Finally, American International Group Inc. boosted its position in REGENXBIO by 7.1% during the 1st quarter. American International Group Inc. now owns 12,468 shares of the biotechnology company’s stock worth $241,000 after acquiring an additional 822 shares during the period. Institutional investors own 73.23% of the company’s stock.

Several equities research analysts have recently commented on the company. BidaskClub upgraded REGENXBIO from a “hold” rating to a “buy” rating in a research note on Saturday, August 12th. Zacks Investment Research upgraded REGENXBIO from a “hold” rating to a “buy” rating and set a $23.00 price objective for the company in a research report on Saturday, August 12th. Evercore ISI assumed coverage on REGENXBIO in a research report on Wednesday, August 16th. They issued an “outperform” rating and a $25.00 price objective for the company. Finally, Chardan Capital reiterated a “buy” rating and issued a $75.00 price objective (up previously from $55.00) on shares of REGENXBIO in a research report on Tuesday. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus price target of $37.00.

About REGENXBIO

REGENXBIO Inc is a clinical-stage biotechnology company. The Company’s gene therapy product candidates are designed to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. The Company develops products candidates across the therapeutic areas of metabolic, neurodegenerative and retinal diseases.

Insider Buying and Selling by Quarter for REGENXBIO (NASDAQ:RGNX)

Receive News & Ratings for REGENXBIO Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for REGENXBIO Inc. and related companies with MarketBeat.com's FREE daily email newsletter.